G1 Therapeutics (GTHX) Stock Rating Upgraded by BidaskClub

G1 Therapeutics (NASDAQ:GTHX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Other research analysts have also recently issued reports about the company. BTIG Research assumed coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $31.40.

G1 Therapeutics (GTHX) opened at $25.35 on Tuesday. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, November 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. equities research analysts forecast that G1 Therapeutics will post -2.72 EPS for the current fiscal year.

In related news, insider Rajesh Malik sold 3,776 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total transaction of $86,696.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $20.01, for a total value of $4,002,000.00. The disclosure for this sale can be found here. Insiders have sold 545,932 shares of company stock valued at $10,848,385 over the last ninety days.

A number of hedge funds and other institutional investors have recently modified their holdings of GTHX. American International Group Inc. acquired a new position in G1 Therapeutics during the third quarter valued at approximately $130,000. California State Teachers Retirement System acquired a new position in G1 Therapeutics during the third quarter valued at approximately $319,000. Schwab Charles Investment Management Inc. acquired a new position in G1 Therapeutics during the third quarter valued at approximately $364,000. Bank of New York Mellon Corp acquired a new position in G1 Therapeutics during the third quarter valued at approximately $568,000. Finally, Alps Advisors Inc. boosted its position in G1 Therapeutics by 9.1% during the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after purchasing an additional 2,317 shares during the last quarter. 43.25% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2018/01/23/g1-therapeutics-gthx-stock-rating-upgraded-by-bidaskclub.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit